Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for allegedly failing to disclose critical information regarding its business prospects, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic challenges and maintain financial flexibility for dividends, while understating the negative impacts of competitive pressures, declining global sales, and product oversupply [2]. - On June 23, 2025, BMO downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, resulting in a 3.21% drop in stock price to $26.87 [3]. - Dow reported disappointing Q2 2025 results on July 24, 2025, with a non-GAAP loss per share of $0.42, exceeding analyst expectations of a loss between $0.17 and $0.18. Net sales were $10.1 billion, a 7.3% year-over-year decline, missing estimates by $130 million. Additionally, Dow announced a 50% cut in its dividend, causing a 17.45% drop in stock price to $25.07 [4]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Dow Inc. and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - The lead plaintiff represents other class members in directing the litigation, and shareholders can remain absent class members if they choose not to participate [5]. Group 3: Company Background - Dow Inc. is an American materials science company that serves various industries, including packaging, infrastructure, mobility, and consumer applications [1].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Allegations - The complaint claims that during the class period, C3.ai did not disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - The lawsuit alleges that C3.ai would struggle to achieve its profit and growth potential due to these undisclosed issues [2]. Financial Impact - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by October 21, 2025, to serve as lead plaintiff [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation (NASDAQ: QMCO) for alleged deficiencies in its internal control over financial reporting, leading to improper revenue recognition and the need for restatement of financial statements [1][2]. Allegations - The complaint states that Quantum Corporation failed to disclose improper revenue recognition during the fiscal year ended March 31, 2025 [2]. - As a result of these deficiencies, Quantum Corporation will need to restate its financial statements for the fiscal third quarter ended December 31, 2024 [2]. - The statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [2]. Financial Impact - On August 8, 2025, Quantum Corporation announced that its 3Q24 financials would be restated, reflecting a decrease of approximately $3.9 million in revenue [3]. - The company also disclosed material weaknesses in its internal control over financial reporting and disclosure controls as of December 31, 2024, and March 31, 2025 [3]. Management Changes - Following the financial disclosures, Quantum Corporation's CFO announced resignation on August 18, 2025, after holding the position for less than five months [3].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Company Background - Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs in the U.S. [1] - The lawsuit claims that Unicycive misrepresented the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2]. - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. Group 2: Recent Developments - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party manufacturing vendor, which impacted discussions regarding the drug label [3]. - Following this announcement, Unicycive's stock price dropped over 40% [3]. - On June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA, further citing the cGMP deficiencies, leading to an additional stock price decline of nearly 30%, closing at $4.77 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Unicycive and can contact Robbins LLP to serve as lead plaintiff before the October 14, 2025 deadline [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Charter Communications, Inc. for allegedly misleading investors about its business prospects, particularly regarding the impact of the Affordable Connectivity Program's end on its financial performance [2][3]. Group 1: Allegations and Financial Performance - The lawsuit claims that Charter failed to disclose the material impact of the Affordable Connectivity Program (ACP) ending, which affected Internet customer declines and revenue [2]. - Charter reported an EBITDA of $5.7 billion for Q2 2025, indicating a 0.5% year-over-year growth; however, this growth was attributed to a one-time benefit of $45 million, and without this, EBITDA would have missed estimates by 2.4% and shown a decline of 0.3% year-over-year [3]. - Following the financial results announcement, Charter's stock price dropped by $70.25, or over 18%, closing at $309.75 per share on July 25, 2025 [3]. Group 2: Class Action Participation - Shareholders who purchased Charter securities between July 26, 2024, and July 24, 2025, may be eligible to participate in the class action [1][4]. - Interested shareholders must contact Robbins LLP before the October 14, 2025, deadline to move for lead plaintiff status [4].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation (NASDAQ: QMCO) due to allegations of deficiencies in its internal control over financial reporting, leading to improper revenue recognition and the need to restate financial statements [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Quantum Corporation improperly recognized revenue during the fiscal year ended March 31, 2025, necessitating a restatement of previously filed financial statements for the fiscal third quarter ended December 31, 2024 [2]. - On August 8, 2025, Quantum Corporation announced that its 3Q24 financials could not be relied upon and would be restated, indicating a decrease of approximately $3.9 million in revenue [3]. - The company disclosed material weaknesses in its internal control over financial reporting and disclosure controls as of December 31, 2024, and March 31, 2025 [3]. Group 2: Management Changes - Following the financial disclosures, Quantum Corporation announced the resignation of its CFO on August 18, 2025, after holding the position for less than five months [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Quantum Corporation, with options to serve as lead plaintiff or remain an absent class member [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, due to allegations of misconduct related to Medicare Advantage plans [1][2]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company the most, regardless of the quality of those plans [2]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [2][3]. - The U.S. Department of Justice filed a complaint against SelectQuote, stating that the company received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [3]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]. - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for failing to disclose fraudulent activities by its third-party arbitration vendor, HaloMD, which has raised concerns about the legitimacy of the company's reported revenues and financial health [2][3]. Group 1: Allegations and Concerns - Nutex Health Inc. allegedly engaged in a scheme with HaloMD that defrauded insurance companies, leading to unsustainable revenue figures [2]. - The company is accused of overstating its ability to remediate internal control weaknesses, affecting its financial reporting and stock-based compensation calculations [2]. - A short report by Blue Orca Capital highlighted that Nutex's recent 20-fold share price surge was artificially inflated due to HaloMD's practices, raising doubts about the company's financial performance [3]. Group 2: Financial Impact - Following the announcement of a delay in filing quarterly financial statements due to incomplete accounting adjustments, Nutex's stock price dropped over 16% [4]. - The potential cessation of revenue benefits from HaloMD's billing practices could lead to a significant decline in Nutex's financial performance, possibly reverting its stock to penny-stock levels [3]. Group 3: Legal Proceedings - Shareholders are encouraged to participate in the class action lawsuit against Nutex Health Inc., with options to serve as lead plaintiff or remain an absent class member [5]. - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [6].

Core Points - A class action has been filed against C3.ai, Inc. on behalf of investors who acquired its securities between February 26, 2025, and August 8, 2025 [1] - Allegations include misleading investors about the impact of the CEO's health on the company's business prospects and its ability to close deals [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year, attributing this to CEO health issues and management reorganization [3] Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must submit their papers by October 21, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint asserts that LifeMD's management materially overstated the company's competitive position [2]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - As a result, statements made by the defendants about LifeMD's business operations and prospects were materially false and misleading [2]. Financial Impact - On August 5, 2025, LifeMD revised its full-year 2025 guidance for revenue and adjusted EBITDA due to "temporary challenges" in its RexMD business, which led to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can remain absent class members if they choose not to participate [4]. Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].